Welcome to our dedicated page for Telo Genomics news (Ticker: TDSGF), a resource for investors and traders seeking the latest updates and insights on Telo Genomics stock.
Telo Genomics Corp (OTCQB: TDSGF; TSXV: TELO) regularly publishes news related to its telomere-based diagnostic and prognostic technologies, with a strong emphasis on multiple myeloma and minimal residual disease (MRD) testing. Company updates often describe progress in clinical validation, scientific presentations, and collaborations that support its liquid biopsy and telomere analytics platform.
Recent announcements highlight Telo Genomics’ MRD work in multiple myeloma, including a retrospective blood-based MRD study with the University of Athens and prospective MRD trials with institutions such as Cleveland Clinic and Jewish General Hospital. News items also cover poster presentations and abstract acceptances at major hematology and myeloma meetings, including the American Society of Hematology Annual Meeting and the International Myeloma Society Annual Meeting, where the company showcases its TeloView®-based MRD methodologies.
Investors and observers can find coverage of Telo Genomics’ developments in blood-based MRD workflows, single-cell risk profiling of MRD and circulating tumor cells, and the use of 3D telomere profiling to assess relapse risk and disease progression. Additional news may include operational updates, such as the relocation and expansion of clinical laboratories in the Greater Toronto Area, investor relations agreements, and corporate communications relating to commercialization efforts.
This news page is useful for tracking how Telo Genomics advances its telomere platform, expands its clinical evidence base, and participates in key industry conferences and summits focused on multiple myeloma and precision oncology. Readers interested in TDSGF can use the news feed to follow scientific milestones, clinical collaborations, and corporate disclosures over time.
Telo Genomics (OTCQB: TDSGF) appointed John Price as Chief Financial Officer, effective January 30, 2026. Mr. Price brings over three decades of accounting, financial planning, M&A and capital markets experience and succeeds Christopher Ross, who served as CFO since April 2021.
Mr. Price worked at public companies including Assure Holdings, National Beverage, Alliance MMA and MusclePharm, held finance roles at Silicon Valley technology firms, and began his career at Ernst & Young. He holds a B.S. in Accounting from Pennsylvania State University and has no family ties to company directors or officers.
Telo Genomics (OTCQB:TDSGF) launched a retrospective multiple myeloma Minimal Residual Disease (MRD) study with the University of Athens as part of its 2026 multi-center validation program.
The study uses well-characterized blood samples with an average of ~3 years follow-up and existing serial Next-Generation Flow (NGF) MRD results in blood and bone marrow to compare performance to Telo's blood-based TeloView®MRD. TeloView®MRD targets a claimed limit of detection of 1 in 10^7 cells versus NGF sensitivity near 10^6 in some centers. Telo also cites ongoing prospective MRD trials with Cleveland Clinic and Jewish General Hospital and expects additional retrospective collaborations in Q1 2026.
Telo Genomics (OTCQB: TDSGF) presented initial clinical results for a peripheral blood MRD test in multiple myeloma at the 67th ASH meeting on December 11, 2025.
The poster describes a combined approach that enumerates individual circulating tumor cells and applies TeloView 3D telomere profiling, reporting a limit of detection of 1 in 107 cells and identification of distinct 3D genome clusters that correlate with high/low mutation patterns. The abstract was published in Blood and the poster is available on the company website. Larger validation studies are underway to assess predictive power for relapse risk.
Telo Genomics (OTCQB: TDSGF) will present at the Myeloma Canada MRD Testing Implementation Summit on November 14–15, 2025. Dr. Yulia Shifrin will introduce initial clinical results for a blood-based MRD workflow combined with the TeloView® platform that enables individual-cell risk‑profiling.
Early findings report distinct single-cell genomic and structural profiles in myeloma patients that correlate with relapse risk, yielding a quantifiable relapse‑risk score that supplements traditional MRD positivity/negativity.
Telo Genomics (OTCQB: TDSGF) announced that the American Society of Hematology (ASH) accepted its abstract for a poster at the 67th ASH Annual Meeting (Dec 6-9, 2025, Orlando).
Dr. Yulia Shifrin will present Telo's telomere-based Minimal Residual Disease (MRD) methodology that pairs MRD assessment with single-cell risk profiling using the TeloView platform. The abstract will be published in a November supplemental issue of Blood, with full details available after November 3, 2025. The company described the approach as a non-invasive liquid biopsy intended to provide actionable relapse-risk information for clinicians.
Management said ASH acceptance underscores progress toward clinical adoption and broader recognition of Telo's diagnostic technology in the precision oncology diagnostics market.
Telo Genomics (OTCQB: TDSGF) has announced the relocation of its clinical laboratories from the MaRS startup incubation hub to a new, larger state-of-the-art facility at 555 Richmond Street West in Toronto. The expansion comes in response to increasing demand for their diagnostic tests and growing volume of clinical and research samples.
The company, which specializes in diagnostic and prognostic tests through telomere analysis, began operations at the new facility on September 29, 2025. Additionally, the company announced the resignation of Hugh Rogers from its Board of Directors.
Telo Genomics (OTCQB: TDSGF) presented a groundbreaking poster abstract on minimal residual disease (MRD) at the 22nd International Myeloma Society Annual Meeting in Toronto. The presentation introduced a novel workflow combining Multiple Myeloma (MM) Circulating Tumor Cells (CTCs) enumeration with TeloView® 3D telomere profiling platform.
The innovative methodology offers a less invasive biomarker for Multiple Myeloma by analyzing peripheral blood instead of bone marrow. This approach provides functional and biologically actionable data beyond traditional enumeration methods, helping assess disease progression risk. The abstract will be published in the Clinical Lymphoma, Myeloma, & Leukemia Journal.
Telo Genomics (OTCQB: TDSGF) has engaged Hayden IR, LLC as its investor relations consulting firm to enhance investor awareness and communication strategy. The 12-month agreement, effective August 20, 2025, includes a monthly fee of US$7,500.
For the first four months, US$3,500 of the monthly fee (totaling US$14,000) will be accrued and payable upon either Telo's next financing closing or January 31, 2026. The agreement includes a 30-day termination notice option for both parties.
Telo Genomics (OTCQB: TDSGF) announced its participation in the upcoming OTCQB Venture Virtual Investor Conference on August 7th, 2025. Guido Baechler, Executive Chairman of the Board, will present the company's strategy for accelerating development and commercialization of multiple myeloma MRD and smoldering myeloma assay applications.
The live, interactive presentation is scheduled for 1:00 PM - 1:30 PM ET, allowing investors to engage directly with the company through a Q&A session. An archived webcast will be available for those unable to attend the live event.
Telo Genomics (OTCQB: TDSGF) announced the acceptance of its abstract on minimal residual disease (MRD) for presentation at the 22nd International Myeloma Society Annual Meeting in Toronto, from September 17-20, 2025. The abstract, titled "3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression," will be presented by Dr. Yulia Shifrin and published in Clinical Lymphoma, Myeloma & Leukemia.
The presentation will showcase TeloView MM-MRD's proprietary approach to counting and profiling individual MRD cells, which could help clinicians assess relapse risk. Additionally, the company issued 411,539 common shares to Trusted Health Advisors LLC for services related to partnering and commercialization, valued at approximately $50,369.
FAQ
What is the current stock price of Telo Genomics (TDSGF)?
What is the market cap of Telo Genomics (TDSGF)?
